Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SHR-9839 + SHR-A1921
- Development stage
- Unknown
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
SHR-9839 + SHR-A1921 is a combination of two investigational drugs, both developed by Hengrui Pharmaceutical. SHR-9839 is a humanized antibody drug designed to treat advanced malignant tumors by simultaneously blocking two key signaling pathways implicated in tumor development[1]. SHR-A1921 is an antibody-drug conjugate (ADC) targeting the TROP2 tumor-associated antigen; after binding to TROP2 on tumor cells, it is internalized and releases a cytotoxic small molecule payload to induce tumor cell death[1][5]. This combination is under clinical investigation for advanced solid tumors, including non-small cell lung cancer and platinum-resistant ovarian cancer[2][3][5].
- Other names
- SHR-9839 for injectionSHR9839 for injectionSHR 9839 for injectionSHR-A1921 for injectionSHR-A-1921 for injectionSHR-A 1921 for injection
02
Targets
TACSTD2 (Tumor-associated calcium signal transducer 2)EGFR T790M (Epidermal growth factor receptor T790M mutant)MET (Mesenchymal-epithelial transition factor receptor)TOP1 (DNA Topoisomerase I)
Beyond the preview
Go deeper on SHR-9839 + SHR-A1921.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SHR-9839 + SHR-A1921.